ALZN
Alzamend Neuro, Inc.Company Information
- Company Name
- Alzamend Neuro, Inc.
- CIK
- CIK0001677077
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ALZN: Nasdaq
- Fiscal Year End
- April 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALZN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-14
- Last sale
- 2026-08-26
- Shares purchased (TTM)
- 110,388
- Shares sold (TTM)
- 266,966
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,719,500
- Shares outstanding
- 4,478,709
- Ownership
- 60.72%
Earnings Market Reaction
- Filing date
- 2026-09-10
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 1 | 3 | 4 | 6 | 4 | 3 | 4 | 1 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | ||||||
| Assets Current | 8 | 2 | 4 | 5 | 6 | 4 | 4 | 5 | 1 | 0 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 9 | 2 | 4 | 5 | 6 | 5 | 4 | 5 | 2 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 4 | 4 | ||||||
| Liabilities Current | - | - | - | - | - | - | - | - | - | - | 4 | - | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Liabilities | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 5 | 4 | ||||||
Statement Of Stockholders Equity | ||||||||||||||||||
| Extended Product Warranty Accrual Noncurrent | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Preferred Stock Value | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Mezzanine Equity | ||||||||||||||||||
| Temporary Equity Value Excluding Additional Paid In Capital | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Additional Paid In Capital | 76 | 68 | 67 | 67 | 67 | 63 | 61 | 60 | 54 | 51 | 49 | 63 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | - | - | - | - | -0 | - | ||||||
| Retained Earnings Accumulated Deficit | -70 | -67 | -64 | -62 | -61 | -59 | -57 | -56 | -55 | -54 | -53 | -51 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 6 | 1 | 2 | 4 | 5 | 4 | 3 | 4 | -1 | -3 | -4 | -3 | ||||||
| Liabilities And Stockholders Equity | 9 | 2 | 4 | 5 | 6 | 5 | 4 | 5 | 2 | 1 | 1 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 5 | 4 | 4 | 4 | 3 | 1 | 6 | 5 | 1 | 0 | 7 | 6 | ||||||
| Shares Outstanding | 5 | 4 | 4 | 4 | 3 | 1 | 6 | 5 | 1 | 0 | 7 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAlzamend Neuro, Inc. (ALZN) — SEC Financial Statements & Analysis
Alzamend Neuro, Inc. (ALZN) is a pharmaceutical preparations company, incorporated in DE. Alzamend Neuro, Inc. trades on Nasdaq as: ALZN. Alzamend Neuro, Inc. (ALZN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-10. Based on that filing, Alzamend Neuro, Inc. carries a market cap of $5.87M, a P/E ratio of -0.64x, a P/B ratio of 1.01x, an enterprise value of $-1.72M, and an EV/EBITDA multiple of 0.19x. On profitability, it posts a Return on Equity (ROE) of -163.23%, a Return on Assets (ROA) of -122.36%, and a Return on Invested Capital (ROIC) of -41661.55%. Per share, it reports EPS of $-2.03, diluted EPS of $-2.03, free cash flow per share of $-1.53, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 45.71% year-over-year and EPS growth of -31.48% year-over-year. On the balance sheet, it maintains a current ratio of 0.16x, a quick ratio of 0.07x, working capital of $-3.23M, a debt-to-equity ratio of -1.07x, a debt ratio of 5.84, an interest coverage ratio of -1480.55x, free cash flow of $-6.84M (TTM), and net debt of $-7.59M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.87M
- P/E TTM
- -0.64x
- EPS TTM
- $-2.03
- P/B TTM
- 1.01x
- ROE TTM
- -163.23%
- ROA TTM
- -122.36%
- Debt To Equity
- -1.07x
- Free Cash Flow TTM
- $-6.84M
Data as of 2026-07-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alzamend Neuro, Inc. in?
Alzamend Neuro, Inc. (ALZN) operates in the Pharmaceutical Preparations industry.
What exchange does ALZN trade on?
Alzamend Neuro, Inc. (ALZN) trades on the Nasdaq.
Where is Alzamend Neuro, Inc. incorporated?
Alzamend Neuro, Inc. is incorporated in DE.
When was Alzamend Neuro, Inc. (ALZN)'s most recent SEC filing?
Alzamend Neuro, Inc. (ALZN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-10.
What is ALZN's market cap?
Alzamend Neuro, Inc. (ALZN) has a market capitalization of $5.87M as of 2026-07-31.
What is ALZN's EPS (earnings per share)?
Alzamend Neuro, Inc. (ALZN)'s trailing twelve month EPS is $-2.03 as of 2026-07-31.
What is ALZN's ROE (return on equity)?
Alzamend Neuro, Inc. (ALZN)'s trailing twelve month Return on Equity (ROE) is -163.23% as of 2026-07-31.
What is ALZN's ROA (return on assets)?
Alzamend Neuro, Inc. (ALZN)'s trailing twelve month Return on Assets (ROA) is -122.36% as of 2026-07-31.
What is ALZN's ROIC (return on invested capital)?
Alzamend Neuro, Inc. (ALZN)'s trailing twelve month Return on Invested Capital (ROIC) is -41661.55% as of 2026-04-30.
What is ALZN's EV/EBITDA?
Alzamend Neuro, Inc. (ALZN)'s trailing twelve month EV/EBITDA is 0.19x as of 2026-07-31.